Humacyte/$HUMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Humacyte
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Ticker
$HUMA
Sector
Primary listing
Employees
219
Headquarters
Website
Humacyte Metrics
BasicAdvanced
$249M
-
-$0.44
1.90
-
Price and volume
Market cap
$249M
Beta
1.9
52-week high
$6.77
52-week low
$1.15
Average daily volume
4.7M
Financial strength
Current ratio
2.453
Quick ratio
1.804
Long term debt to equity
1,936.204
Total debt to equity
2,066.264
Interest coverage (TTM)
-7.50%
Profitability
EBITDA (TTM)
-103.92
Gross margin (TTM)
-9,846.94%
Net profit margin (TTM)
-7,171.27%
Operating margin (TTM)
-13,598.04%
Management effectiveness
Return on assets (TTM)
-50.18%
Return on equity (TTM)
484.10%
Valuation
Price to revenue (TTM)
256.034
Price to book
60.58
Price to tangible book (TTM)
60.58
Price to free cash flow (TTM)
-1.97
Free cash flow yield (TTM)
-50.75%
Free cash flow per share (TTM)
-0.797
Growth
Earnings per share change (TTM)
-65.79%
3-year revenue growth (CAGR)
-25.17%
3-year earnings per share growth (CAGR)
12.31%
What the Analysts think about Humacyte
Analyst ratings (Buy, Hold, Sell) for Humacyte stock.
Humacyte Financial Performance
Revenues and expenses
Humacyte Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Humacyte stock?
Humacyte (HUMA) has a market cap of $249M as of September 17, 2025.
What is the P/E ratio for Humacyte stock?
The price to earnings (P/E) ratio for Humacyte (HUMA) stock is 0 as of September 17, 2025.
Does Humacyte stock pay dividends?
No, Humacyte (HUMA) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Humacyte dividend payment date?
Humacyte (HUMA) stock does not pay dividends to its shareholders.
What is the beta indicator for Humacyte?
Humacyte (HUMA) has a beta rating of 1.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.